1 |
周俊彦, 王玉堂, 单兆亮. 炎症与心房颤动的关系研究 [J]. 中国康复理论与实践, 2006, 12(2): 2.
|
2 |
胡大一, 孙艺红. 我国心房颤动的诊治进展—心房颤动的病因和流行病学 [J]. 中国实用内科杂志, 2006, 26(2): 2.
|
3 |
Wang YJ, Li ZX, Gu HQ, et al. China Stroke Statistics: an update on the 2019 report from the National Center for Healthcare Quality Management in Neurological Diseases, China National Clinical Research Center for Neurological Diseases, the Chinese Stroke Association, National Center for Chronic and Non-communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention and Institute for Global Neuroscience and Stroke Collaborations [J]. Stroke Vasc Neurol, 2022, 7(5): 415-450.
|
4 |
中国心血管健康与疾病报告编写组, 胡盛寿. 中国心血管健康与疾病报告2020概要 [J]. 中国循环杂志, 2021, 36(6): 25.
|
5 |
Ponikowski P, Voors AA, Anker SD, et al. [2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure] [J]. Kardiol Pol, 2016, 74(10): 1037-1147.
|
6 |
Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines and the Heart Failure Society of America [J]. Circulation, 2017, 136(6): e137-e161.
|
7 |
王华, 梁延春. 中国心力衰竭诊断和治疗指南2018 [J]. 中华心血管病杂志, 2018, 46(10): 760-89.
|
8 |
Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS [J]. Eur Heart J, 2016, 37(38): 2893-2962.
|
9 |
王玉堂. 老年心房颤动患者的综合管理 [J]. 中华老年心脑血管病杂志, 2017, 19(12): 1233-1235.
|
10 |
Staerk L, Wang B, Preis SR, et al. Lifetime risk of atrial fibrillation according to optimal, borderline, or elevated levels of risk factors: cohort study based on longitudinal data from the Framingham Heart Study [J]. BMJ, 2018, 361: k1453.
|
11 |
Benjamin EJ, Muntner P, Alonso A, et al. Heart disease and stroke statistics-2019 update: A report from the American Heart Association [J]. Circulation, 2019, 139(10): e56-e528.
|
12 |
杨丹丹, 李学斌. 心房颤动合并心力衰竭的治疗进展 [J]. 中国实用内科杂志, 2020, 40(3): 4.
|
13 |
孟宪辉, 刘明, 熊鹏, 等. 基于黎曼流形稀疏编码的阵发性房颤检测算法 [J]. 生物医学工程学杂志, 2020, 37(4): 9.
|
14 |
陶然, 叶茂, 陈庆兴, 等. 沉默性心房颤动诊疗进展 [J]. 上海医学, 2021, 44(12): 5.
|
15 |
吴书林. 重视心房颤动的上游治疗 [J]. 中华心血管病杂志, 2020, 48(12): 993-994.
|
16 |
Camm AJ, Naccarelli GV, Mittal S, et al. The increasing role of rhythm control in patients with atrial fibrillation: JACC state-of-the-art review [J]. J Am Coll Cardiol, 2022, 79(19): 1932-1948.
|
17 |
Lacoste JL, Szymanski TW, Avalon JC, et al. Atrial fibrillation management: A comprehensive review with a focus on pharmacotherapy, rate, and rhythm control strategies [J]. Am J Cardiovasc Drugs, 2022, 22(5): 475-496.
|
18 |
Lee MY, Han S, Bang OY, et al. Drug utilization pattern of oral anticoagulants in patients with atrial fibrillation: A nationwide population-based study in Korea [J]. Adv Ther, 2022, 39(7): 3112-3130.
|
19 |
Lan B, Cheng G, Bai Y, et al. Efficacy and safety of left atrial appendage occlusion in mild mitral stenosis patients with high bleeding risk [J]. Int Heart J, 2022, 63(3): 492-497.
|
20 |
Aldaas OM, Lupercio F, Darden D, et al. Meta-analysis of the usefulness of catheter ablation of atrial fibrillation in patients with heart failure with preserved ejection fraction [J]. Am J Cardiol, 2021, 142: 66-73.
|
21 |
Packer DL, Piccini JP, Monahan KH, et al. Ablation versus drug therapy for atrial fibrillation in heart failure: Results from the CABANA trial [J]. Circulation, 2021, 143(14): 1377-1390.
|
22 |
Gencher JA, Hawkins NM, Deyell MW, et al. Management of atrial Tachyarrhythmias in heart failure-an interventionalist's point of view [J]. Curr Heart Fail Rep, 2022, 19(3): 126-135.
|
23 |
Blair H A. Dapagliflozin: A review in symptomatic heart failure with reduced ejection fraction [J]. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2021, 21(6): 701-710.
|
24 |
Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: A report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines [J]. Circulation, 2022, 145(18): e895-e1032.
|
25 |
Healey JS, Oldgren J, Ezekowitz M, et al. Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation: a cohort study [J]. Lancet, 2016, 388(10050): 1161-1169.
|
26 |
Rienstra M, Hobbelt AH, Alings M, et al. Targeted therapy of underlying conditions improves sinus rhythm maintenance in patients with persistent atrial fibrillation: results of the RACE 3 trial [J]. Eur Heart J, 2018, 39(32): 2987-2996.
|
27 |
Du X, Dong J, Ma C. Is Atrial Fibrillation a Preventable Disease? [J]. J Am Coll Cardiol, 2017, 69(15): 1968-1982.
|
28 |
Middeldorp ME, Pathak RK, Meredith M, et al. PREVEntion and regReSsive Effect of weight-loss and risk factor modification on Atrial Fibrillation: the REVERSE-AF study [J]. Europace, 2018, 20(12): 1929-1935.
|